NASDAQ: HUGEFsd Pharma Inc Stock
$0.30-0.01 (-3.23%)
Updated May 31, 2024
HUGE Price
$0.30
Fair Value Price
$0.04
Market Cap
$12.13M
52 Week Low
$0.27
52 Week High
$1.68
P/E
-1.58x
P/B
1.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.33
Operating Cash Flow
-$6M
Beta
1.03
Next Earnings
Jul 18, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HUGE Overview
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Zen Score
–
Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HUGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HUGE ($0.30) is overvalued by 575.15% relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HUGE ($0.30) is not significantly undervalued (575.15%) relative to our estimate of its Fair Value price of $0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HUGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HUGE due diligence checks available for Premium users.
Be the first to know about important HUGE news, forecast changes, insider trades & much more!
HUGE News
Valuation
HUGE fair value
Fair Value of HUGE stock based on Discounted Cash Flow (DCF)
Price
$0.30
Fair Value
$0.04
Overvalued by
575.15%
HUGE ($0.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HUGE ($0.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HUGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HUGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.58x
Industry
0.92x
Market
28.44x
HUGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.38x
Industry
2.17x
HUGE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HUGE's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.4M
Profit Margin
0%
HUGE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.4M
Liabilities
$2.9M
Debt to equity
0.33
HUGE's short-term assets ($6.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HUGE's short-term assets ($6.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HUGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
-$16.3k
Financing
$418.2k
HUGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HUGE vs Pharmaceutical Stocks
Fsd Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.